Turning Point Brands, Inc. (NYSE: TPB) has announced that it will hold a conference call on November 5 at 8:30 a.m. ET to discuss its third-quarter 2025 results, accessible via U.S. toll-free (800-715-9871) or international (+1-646-307-1963) with Event ID 6640134.

A live webcast will be accessible on the company’s investor relations website, with a replay uploaded 2 hours after the call. Ahead of the call, Turning Point also shared a summary of its second-quarter 2025 financial results.

• Net sales rose 25.1% year-over-year to $116.6 million.
• Net income increased 11.3% to $14.5 million, with diluted EPS at $0.79 (up from $0.68 a year ago).
• Adjusted EBITDA grew 14.8% to $30.5 million, and adjusted net income rose 4.5% to $18.0 million.
• The firm’s Modern Oral segment (nicotine pouches/alternative oral products) skyrocketed 651% year-over-year to $30.1 million, representing ~26% of total sales.
• Segmentation: The Stoker’s Products segment (chiefly smokeless tobacco accessories) posted a 62.9% sales increase to $69.6 million, while the Zig-Zag Products segment declined 6.9% to $47.0 million.
• On the cost side, gross profit increased 32.2% to $66.6 million, and gross margin in the Stoker’s segment improved markedly to 62.5%. SG&A rose from $29.2 million to $40.3 million, driven by new “white-pouch” marketing, PMTA-related costs and increased freight.
• Balance-sheet highlights: As of June 30, 2025, total gross debt stood at $300.0 million, net debt at $190.1 million, and total liquidity was $176.4 million (including $109.9 million cash + $66.5 million availability).
• The company raised its full-year 2025 guidance for Adjusted EBITDA to $110.0 – 114.0 million (from $108.0 – 113.0 million) and raised Modern Oral full-year sales outlook to $100.0 – 110.0 million (from $80.0 – 95.0 million).

Given the strong execution in Q2—especially the breakout growth in its Modern Oral business—Turning Point’s upcoming Q3 call will be closely watched for updates on its nicotine pouch strategies, PMTA regulatory status, cost pressures in smokeless tobacco segments, and the competitive landscape for alternative nicotine products.

For investors, analysts, and the tobacco/nicotine industry, the Q2 results highlight how Turning Point is shifting from legacy segments toward growth in modern oral nicotine formats.

The clear shift in the sales mix (now accounting for more than a quarter of revenue) underscores the increased strategic importance of the nicotine-pouch channel. However, higher SG&A costs and the modest growth in net income (compared with revenue) raise questions about margin leverage and cost discipline.

Ahead of Q3, when management speaks on November 5, stakeholders may want to prepare questions or listen for commentary on:

• The pace and profitability of the Modern Oral rollout (products, geographies, channel mix);
• Margin trends within legacy segments (Stoker’s, Zig-Zag) and how the business plans to mitigate the Zig-Zag decline;
• Regulatory developments or PMTA filings for modern oral products;
• Capital spending, debt leverage and liquidity plans given elevated SG&A and growing debt base;
• Competitive environment (other nicotine-pouch players) and pricing/marketing implications.

Investors and industry watchers can dial in as instructed or access the webcast through the company’s website. Note: Participants should call at least 10 minutes before the 8:30 a.m. ET start time and follow the audio prompts to register.